Results 51 to 60 of about 982 (100)

Recent Advances in Radiopharmaceuticals for Cancer Diagnosis and Therapy. [PDF]

Oncol Res
Han YR, Lee SB.
europepmc   +1 more source

Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy. [PDF]

Cancers (Basel)
Laetsch TW, States LJ, Lazow MA, Chauhan A.   +3 more
europepmc   +1 more source

Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Wang Q, Librizzi D, Bagheri S, Ebrahimifard A, Hojjat Shamami A, Rinke A, Eilsberger F, Luster M, Hooshyar Yousefi B.   +8 more
europepmc   +1 more source

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses. [PDF]

EJNMMI Res
Engbers PAM, Reuvers TGA, Heredia-Genestar JM, Chang J, Verkaik NS, Sabatella M, Nonnekens J.   +6 more
europepmc   +1 more source

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [¹⁷⁷Lu]Lu-DOTA-TATE: A post-authorisation safety study. [PDF]

J Neuroendocrinol
Hofland J, Grana CM, Weickert MO, Moore AR, Shah T, Prakash V, Kolasińska-Ćwikła A, de Herder WW, Spada F, Xu L, Fite R, Wu Y, Ćwikła JB.   +12 more
europepmc   +1 more source

Anatomical-biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE. [PDF]

BMC Cancer
Bilgic S, Nazari A, Sağer MS, Sonmezoglu K.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

European Journal of Nuclear Medicine and Molecular Imaging, 2013
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has been demonstrated to be an effective therapeutic option in patients with disseminated neuroendocrine tumours (NET). Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE may improve the efficacy of PRRT without increasing the toxicity. In a phase II study
Ettore Seregni, Marco Maccauro, Carlo Chiesa   +2 more
exaly   +3 more sources

Estimate of activity discharged into the sewer network in neuroendocrine treatments with 177Lu-DOTA-TATE

Applied Radiation and Isotopes, 2022
The urine of patients treated for neuroendocrine tumors with 177Lu is a liquid radioactive waste. The total body activity retained by the patient is quantified with SPECT-CT image 1 day after administration. From the activity of 177Lu in patient after 1 day Apat_Lu177_1d, the activity in urine after 1 day Aurine_Lu177_1d is determined, as well as the ...
Raquel Barquero, Javier Velasco, Carlos Andres, Ricardo Torres, Ricardo Ruano   +4 more
openaire   +2 more sources